IA
KPTI icon

Insight Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Insight Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,184
Closed -$306K – 329
2021
Q1 		$306K Buy
2,184
+1,036
+90% +$218K 0.1% 257
2020
Q4 		$267K Buy
+1,148
New +$266K 0.1% 227

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Insight Advisors's KPTI Position: Q2 2021 in Review

Insight Advisors sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 2,184 shares — an estimated $306K sold.

Insight Advisors first reported a position in KPTI in Q4 2020 and held it in 2 quarters. The position peaked at $306K in Q1 2021. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • Insight Advisors reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Insight Advisors sold 2,184 Karyopharm Therapeutics shares in Q2 2021, an estimated $306K.
  • Insight Advisors first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 2 quarters.
  • Insight Advisors's Karyopharm Therapeutics position peaked at $306K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Insight Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.